CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit TranscriptSeeking Alpha • 02/18/26
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026The Motley Fool • 02/13/26
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/13/26
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 02/12/26
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/03/26
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research • 02/02/26
CRISPR Therapeutics AG (CRSP) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 01/24/26
CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True?Zacks Investment Research • 01/12/26
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 MilestonesGlobeNewsWire • 01/12/26
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/26
These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026?The Motley Fool • 12/26/25